is bpc 157 subcutaneous or intramuscular bpc-157 clinical trials dosage BPC-157 Dosing (Common Protocols), 🔹 Oral / Subcutaneous, • 500 mcg daily, • Duration: 6 weeks, 🔹 / Peritendinous, • 1 mg daily, • Duration: 6 weeks, ⚠️ Note:, Not approved by FDA BPC-157 Oral vs Injection: Benefits,

Ligament healing studies demonstrate similar benefits, with BPC-157 showing consistent functional, biomechanical, macroscopic, and histological improvements

Subcutaneous and intramuscular injections offer similar bioavailability

Too low and it loses bacteriostatic efficacy meaning microbial growth becomes a real possibility in a multi-use vial

Naltrexone content remains 8 mg in both strengths, a dosage selected to minimize gastrointestinal discomfort while sustaining receptor occupancy

Platelet Rich Plasma Platelet-rich plasma, or PRP, is a treatment that has been around for over a decade, although it is still considered experimental by some insurance companies

Correct hypokalemia promptly if it develops